MAIA Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on developing oncology drug candidates to improve and extend the lives of people with cancer. The Company’s pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers. The Company’s THIO (6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is a telomere-targeting agent in clinical development. THIO is followed by Libtayo for the treatment of advanced non-small-cell lung cancer. The Company is advancing THIO in Phase II clinical study in Non-Small Cell Lung Cancer. The Company’s second-generation program is engaged in discovering new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. The second-generation pipeline of potential telomere-targeting agents includes five compounds that have undergone in vitro inhibitory testing in five cancer models.